Movement Alert｜DotBio-B Rises 6.03% in Regular Trading, Intensive Buybacks and ASCO Clinical Data Catalyze Rebound

Market Focus06-05

On June 5, DotBio-B rose 6.03% in regular trading, trading at 194.3 HKD/share, with trading volume of approximately 58.48 million HKD.

On the news front, the company has conducted intensive share repurchases over the past three trading days from June 2 to June 4, buying back 64,500 shares, 37,100 shares, and 34,000 shares respectively, spending a combined total of approximately 27.23 million HKD. Simultaneously, the company announced on June 4 a proposal to authorize the repurchase of up to 10% of total issued shares, equivalent to approximately 9.04 million shares, further signaling management confidence in the stock.

Additionally, at the 2026 ASCO Annual Meeting, Phase 1a dose-escalation and safety expansion data for DB-1312/BG-C9074 (a B7-H4 ADC co-developed with BeiGene) in advanced solid tumors were presented via rapid oral report on June 2, providing clinical pipeline catalysts. The broader biotech sector also rallied, with Kelun-Biotech up 5.48%, Innovent Bio up 3.6%, and Akeso up 2.56%, creating positive sector sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170409086?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170409086","market":"hk","top_or_hot":-1,"title":"Movement Alert｜DotBio-B Rises 6.03% in Regular Trading, Intensive Buybacks and ASCO Clinical Data Catalyze Rebound","media":"Market Focus","content":"<p><p>On June 5, DotBio-B rose 6.03% in regular trading, trading at 194.3 HKD/share, with trading volume of approximately 58.48 million HKD.</p><p>On the news front, the company has conducted intensive share repurchases over the past three trading days from June 2 to June 4, buying back 64,500 shares, 37,100 shares, and 34,000 shares respectively, spending a combined total of approximately 27.23 million HKD. Simultaneously, the company announced on June 4 a proposal to authorize the repurchase of up to 10% of total issued shares, equivalent to approximately 9.04 million shares, further signaling management confidence in the stock.</p><p>Additionally, at the 2026 ASCO Annual Meeting, Phase 1a dose-escalation and safety expansion data for DB-1312/BG-C9074 (a B7-H4 ADC co-developed with BeiGene) in advanced solid tumors were presented via rapid oral report on June 2, providing clinical pipeline catalysts. The broader biotech sector also rallied, with Kelun-Biotech up 5.48%, Innovent Bio up 3.6%, and Akeso up 2.56%, creating positive sector sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DotBio-B Rises 6.03% in Regular Trading, Intensive Buybacks and ASCO Clinical Data Catalyze Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DotBio-B Rises 6.03% in Regular Trading, Intensive Buybacks and ASCO Clinical Data Catalyze Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 5, DotBio-B rose 6.03% in regular trading, trading at 194.3 HKD/share, with trading volume of approximately 58.48 million HKD.</p><p>On the news front, the company has conducted intensive share repurchases over the past three trading days from June 2 to June 4, buying back 64,500 shares, 37,100 shares, and 34,000 shares respectively, spending a combined total of approximately 27.23 million HKD. Simultaneously, the company announced on June 4 a proposal to authorize the repurchase of up to 10% of total issued shares, equivalent to approximately 9.04 million shares, further signaling management confidence in the stock.</p><p>Additionally, at the 2026 ASCO Annual Meeting, Phase 1a dose-escalation and safety expansion data for DB-1312/BG-C9074 (a B7-H4 ADC co-developed with BeiGene) in advanced solid tumors were presented via rapid oral report on June 2, providing clinical pipeline catalysts. The broader biotech sector also rallied, with Kelun-Biotech up 5.48%, Innovent Bio up 3.6%, and Akeso up 2.56%, creating positive sector sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1170409086","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170409086","pubTimestamp":1780624305,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 5, DotBio-B rose 6.03% in regular trading, trading at 194.3 HKD/share, with trading volume of approximately 58.48 million HKD.On the news front, the company has conducted intensive share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"动向提示|DotBio-B常规交易涨6.03%密集回购及ASCO临床数据催化反弹","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On June 5, DotBio-B rose 6.03% in regular trading, trading at 194.3 HKD/share, with trading volume of approximately 58.48 million HKD.On the news front, the company has conducted intensive share repurchases over the past three trading days from June 2 to June 4, buying back 64,500 shares, 37,100 shares, and 34,000 shares respectively, spending a combined total of approximately 27.23 million HKD. Simultaneously, the company announced on June 4 a proposal to authorize the repurchase of up to 10% of total issued shares, equivalent to approximately 9.04 million shares, further signaling management confidence in the stock.Additionally, at the 2026 ASCO Annual Meeting, Phase 1a dose-escalation and safety expansion data for DB-1312/BG-C9074 (a B7-H4 ADC co-developed with BeiGene) in advanced solid tumors were presented via rapid oral report on June 2, providing clinical pipeline catalysts. The broader biotech sector also rallied, with Kelun-Biotech up 5.48%, Innovent Bio up 3.6%, and Akeso up 2.56%, creating positive sector sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170409086","isCrawlerRequest":true}